Wei Xiuzhen, Liu Yinghai, Wang Huijuan, Yang Qingqing, Zhang Baihong, Liu Qianyu, Zhu Yuan, Zhu Lingling, Zhang Zhengjie
Department of Oncology, Wu Wei Liang Zhou Hospital, Wuwei, Gansu, China.
Department of Oncology, 940th Hospital of Joint Logistics Support Force of People's Liberation Army, Lanzhou, Gansu, China.
Discov Oncol. 2025 Sep 2;16(1):1673. doi: 10.1007/s12672-025-03521-z.
To investigate the values of systemic inflammatory response index (SIRI) and its dynamic changes in predicting the efficacy and evaluating the prognosis of immunotherapy for advanced cancers.
A retrospective analysis was conducted on the clinical data of 245 patients with locally advanced and advanced cancers who received immune checkpoint inhibitors (ICI) treatment at the 940 Hospital of the Joint Logistics Support Force from June 2020 to June 2023.The χ2-test was used to compare the clinical pathological characteristics of patients in the disease control group and the no-control group, and Kruskal-Wallis test was used to compare the differences in SIRI pre-treatment, disease remission, and disease progression. The correlation between SIRI and progression free survival (PFS) of patients was analyzed using Kaplan-Meier survival curve and Log-rank test; and factors affecting PFS in cancer patients receiving ICIs treatment were analyzed through univariate and multivariate COX regression analysis.
There was a significant difference in the number of treatment lines between the disease control group and no-control group ( = 0.042), but no significant differences were observed in gender, age, tumor differentiation, number of metastatic organs and treatment plan between the two groups ( > 0.05). Compared with pre-treatment, the SIRI decreased during disease remission and increased again during disease progressed. Kaplan- Meier survival curves indicated that patients with high SIRI had shorter PFS than those with low SIRI ( 0.019, < 0.001, 0.012). Univariate and multivariate COX regression analysis revealed that pre-treatment high SIRI (HR = 2.804,95%CI 1.150 ~ 6.838, = 0.023) and disease remission high SIRI (HR = 2.469,95%CI 1.513 ~ 4.029, <0.001) were independent risk factors for PFS in cancer patients undergoing immunotherapy.
The inflammatory index SIRI can be a dynamic biomarker for evaluating the efficacy and prognosis of advanced cancer patients receiving ICI treatment.
探讨全身炎症反应指数（SIRI）及其动态变化在预测晚期癌症免疫治疗疗效和评估预后中的价值。
回顾性分析2020年6月至2023年6月在联勤保障部队第九四〇医院接受免疫检查点抑制剂（ICI）治疗的245例局部晚期和晚期癌症患者的临床资料。采用χ2检验比较疾病控制组和非疾病控制组患者的临床病理特征，采用Kruskal-Wallis检验比较治疗前、疾病缓解和疾病进展时SIRI的差异。采用Kaplan-Meier生存曲线和Log-rank检验分析SIRI与患者无进展生存期（PFS）的相关性；通过单因素和多因素COX回归分析探讨影响接受ICI治疗的癌症患者PFS的因素。
疾病控制组和非疾病控制组的治疗线数有显著差异（=0.042），但两组在性别、年龄、肿瘤分化、转移器官数量和治疗方案方面无显著差异（>0.05）。与治疗前相比，疾病缓解时SIRI降低，疾病进展时再次升高。Kaplan-Meier生存曲线表明，SIRI高的患者PFS短于SIRI低的患者（0.019，<0.001，0.012）。单因素和多因素COX回归分析显示，治疗前SIRI高（HR=2.804，95%CI 1.1506.838，=0.023）和疾病缓解时SIRI高（HR=2.469，95%CI 1.5134.029，<0.001）是接受免疫治疗的癌症患者PFS的独立危险因素。
炎症指标SIRI可作为评估晚期癌症患者接受ICI治疗疗效和预后的动态生物标志物。
